Silibinin (NSC 651520)

Catalog No.S2357 Batch:S235705

Print

Technical Data

Formula

C25H22O10
Molecular Weight 482.44 CAS No. 22888-70-6
Solubility (25°C)* In vitro DMSO 96 mg/mL (198.98 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Silibinin (NSC 651520, Silybin, Silibinin A, Silymarin I, Flavobin), the main flavonoid extracted from the milk thistle Silybum marianum, displays hepatoprotective properties in acute and chronic liver injury.
In vitro Silibinin itself is mixture of two diastereomers silibinin A and silybinin B in approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. [1] Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells. [2] [3] [4]

Protocol (from reference)

Customer Product Validation

Data from [Data independently produced by , , Clin Mol Hepatol, 2015, 21(1):49-59. ]

Selleck's Silibinin (NSC 651520) has been cited by 7 publications

Silibinin inhibits PM2.5-induced liver triglyceride accumulation through enhancing the function of mitochondrial Complexes I and II [ Front Pharmacol, 2024, 15:1435230] PubMed: 39351086
Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway [ Cancer Med, 2024, 13(12):e7393] PubMed: 38923428
A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells [ Med Oncol, 2024, 41(8):188] PubMed: 38918225
Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors [ Int J Mol Sci, 2020, 21(14):5025] PubMed: 32708687
Identification of Small-Molecule Inhibitors of Brucella Diaminopimelate Decarboxylase by Using a High-Throughput Screening Assay. [ Front Microbiol, 2020, 10:2936] PubMed: 32038511
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells [Gu HR, et al. Clin Mol Hepatol, 2015, 21(1):49-59] PubMed: 25834802
Colloidal Aggregation and the in vitro Activity of Traditional Chinese Medicines. [Duan D, et al. ACS Chem Biol, 2015, 10.1021/cb5009487] PubMed: 25606714

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.